Regulation - Nephrology and Hepatology, Oncology

Filter

Popular Filters

UK's NICE recommends new therapy for liver cancer patients

30-07-2013

UK specialist health care company BTG (LSE: BTG) says that the UK's National Institute for Health and…

BiotechnologyBTGEuropeNephrology and HepatologyNordionOncologyRegulation

AVEO and Astellas file NDA for tivozanib in kidney cancer

02-10-2012

USA-based AVEO Oncology (Nasdaq: AVEO) and Japanese drug major Astellas Pharma (TSE:4503) have submitted…

Astellas PharmaAVEO OncologyBiotechnologyNephrology and HepatologyNorth AmericaOncologyPharmaceuticalRegulationtivozanib

Affymax and Takeda get special Medicare code for Omontys

16-04-2012

USA-based Affymax (Nasdaq: AFFY) and the US subsidiary of Japanese drug major Takeda Pharmaceuticals…

AffymaxBiotechnologyNephrology and HepatologyNorth AmericaOmontysOncologypeginesatidePharmaceuticalPricingRegulationTakeda Pharmaceuticals

BTG’s Voraxaze gains first approval, in USA

19-01-2012

The US Food and Drug Administration has approved UK headquartered BTG International’s (LSE: BGC)…

BiotechnologyBTGNephrology and HepatologyNorth AmericaOncologyRegulationVoraxaze

AVEO and Astellas’ tivozanib beats sorafenib in Ph III TIVO-1 trial

04-01-2012

US cancer drug developer AVEO Pharmaceuticals (Nasdaq: AVEO)) and partner Japanese drug major Astellas…

Astellas PharmaAVEO PharmaceuticalsBayerBiotechnologyNephrology and HepatologyNexavarOncologyPharmaceuticalRegulationResearchtivozanib

FDA committee backs Affymax CKD drug

09-12-2011

The US Food and Drug Administration’s Oncologic Drugs Advisory Committee (ODAC) voted 15 to one,…

AffymaxNephrology and HepatologyNorth AmericaOncologypeginesatidePharmaceuticalRegulationTakeda Pharmaceuticals

Back to top